Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 2,250 Shares of Stock

Key Points

• Vaxcyte EVP Jim Wassil sold 2,250 shares for $137,025 at an average price of $60.90 under a pre-arranged Rule 10b5-1 trading plan. He retained 145,435 shares after the sale, a 1.52% reduction in his position.
• Vaxcyte reported quarterly adjusted earnings per share of -$1.99, beating analysts’ consensus estimate of -$2.11.
• Analysts’ consensus rating was “Moderate Buy,” with an average price target of $110.50; the stock traded at $65.68 in the article’s cited session.

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) EVP Jim Wassil sold 2,250 shares of the business's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $60.90, for a total value of $137,025.00. Following the completion of the transaction, the executive vice president owned 145,435 shares in the company, valued at $8,856,991.50. This trade represents a 1.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Monday, October 5th, Jim Wassil sold 18,000 shares of Vaxcyte stock. The stock was sold at an average price of $86.74, for a total value of $1,561,320.00.
• On Thursday, October 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.67, for a total value of $127,507.50.
• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The shares were sold at an average price of $59.52, for a total value of $79,399.68.
• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The shares were sold at an average price of $61.16, for a total value of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The stock was sold at an average price of $61.07, for a total value of $212,340.39.

Vaxcyte Price Performance

PCVX traded up $4.87 during midday trading on Wednesday, hitting $65.68. 2,257,729 shares of the company's stock traded hands, compared to its average volume of 1,640,595. The company has a market cap of $9.77 billion, a PE ratio of -8.61 and a beta of 1.31. The stock's fifty day simple moving average is $61.55 and its 200-day simple moving average is $57.07. Vaxcyte, Inc. has a one year low of $39.87 and a one year high of $90.75.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.11) by $0.12. On average, research analysts expect that Vaxcyte, Inc. will post -7.47 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Zacks Research raised shares of Vaxcyte from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 12th. Wall Street Zen raised shares of Vaxcyte from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Cantor Fitzgerald restated an "overweight" rating and set a $120.00 target price on shares of Vaxcyte in a report on Monday, October 12th. Bank of America reduced their price target on Vaxcyte from $133.00 to $130.00 and set a "buy" rating for the company in a research report on Monday, September 28th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a research report on Friday, October 2nd. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $110.50.

Institutional Trading of Vaxcyte

Large investors have recently modified their holdings of the company. First Light Asset Management LLC raised its holdings in Vaxcyte by 143.4% in the 2nd quarter. First Light Asset Management LLC now owns 345,157 shares of the company's stock worth $20,064,000 after acquiring an additional 203,373 shares during the period. Bank of America Corp DE lifted its position in Vaxcyte by 73.4% during the 1st quarter. Bank of America Corp DE now owns 1,216,843 shares of the company's stock worth $70,711,000 after acquiring an additional 515,209 shares during the last quarter. Candriam S.C.A. acquired a new position in Vaxcyte during the 1st quarter worth $18,306,000. Seven Fleet Capital Management LP lifted its position in Vaxcyte by 406.4% during the 1st quarter. Seven Fleet Capital Management LP now owns 128,450 shares of the company's stock worth $7,464,000 after acquiring an additional 103,085 shares during the last quarter. Finally, Engineers Gate Manager LP acquired a new stake in shares of Vaxcyte in the second quarter valued at about $1,906,000. 96.78% of the stock is owned by institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc NASDAQ: PCVX is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte's lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.